Respiri - Objective measures for better outcomes
Respiri is an Australian medical device and software-as-a-service (SaaS) company, developing a novel remote patient monitoring approach to respiratory health management. Through its integrated wheezo platform (device, application and health portal) the company provides comprehensive (real-time) monitoring for irregular breathing patterns (wheeze), a key physiological variable in asthma and chronic obstructive pulmonary disease (COPD). Following its strategic pivot in 2021, Respiri has redirected its focus to the US market, which has a large inadequately treated patient population and a supportive environment for preventative RPM reimbursement. Employing a cost-effective partner-based strategy, management has recently onboarded its first two (US) hospital clients. We initiate coverage with a valuation of A$189.1m or A$0.24/share.Respiri is engaged in the research, development and commercialization of medical devices, and the development of mobile health applications. Co.'s reportable segments are Australia and Israel.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.